Provided by Tiger Trade Technology Pte. Ltd.

Park Hotels & Resorts Inc.

15.30
-0.5300-3.35%
Pre-market: 15.660.3565+2.33%09:14 EDT
Volume:4.74M
Turnover:72.89M
Market Cap:3.08B
PE:-18.51
High:15.81
Open:15.81
Low:15.26
Close:15.83
52wk High:16.20
52wk Low:9.84
Shares:201.40M
Float Shares:195.63M
Volume Ratio:1.36
T/O Rate:2.42%
Dividend:1
Dividend Rate:6.54%
EPS(TTM):-0.8265
EPS(LYR):-1.4300
ROE:-4.86%
ROA:2.75%
PB:1.00
PE(LYR):-10.70

Loading ...

Court Orders Gym to Repay Mandatory "Performance Competition" Fees Collected from Employee

Deep News
·
Jun 06

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

GlobeNewswire
·
Jun 06

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03

Park Hotels & Resorts updates financial calendar with Q2 earnings release, conference call

Reuters
·
Jun 03

Press Release: Park Hotels & Resorts Inc. Announces Second Quarter 2026 Earnings Conference Call on August 7, 2026

Dow Jones
·
Jun 03

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

GlobeNewswire
·
Jun 03

World Cup Poised to Lift REITs with Full-Service Hotel Exposure -- Market Talk

Dow Jones
·
Jun 03

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
Jun 01

Park Hotels forecasts FY 2026 adjusted EBITDA of $587 million-$617 million

Reuters
·
Jun 01

Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026

GlobeNewswire
·
Jun 01

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

GlobeNewswire
·
May 29

Park Hotels & Resorts (PK) Is Up 9.1% After Strong Q1 RevPAR Beat And Non-Core Asset Sale

Simply Wall St.
·
May 28

Park Hotels & Resorts Is Maintained at Hold by Truist Securities

Dow Jones
·
May 27

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

GlobeNewswire
·
May 26

Truist Raises Price Target on Park Hotels & Resorts to $13 From $12, Keeps Hold Rating

MT Newswires Live
·
May 26

Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

GlobeNewswire
·
May 22

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

GlobeNewswire
·
May 22

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

GlobeNewswire
·
May 19

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

GlobeNewswire
·
May 15

Press Release: Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

Dow Jones
·
May 15